[
    [
        {
            "time": "",
            "original_text": "山西证券---华兰生物一季报点评：业绩符合市场预期，流感疫苗有望持续放量【公司研究】",
            "features": {
                "keywords": [
                    "华兰生物",
                    "一季报",
                    "业绩",
                    "市场预期",
                    "流感疫苗",
                    "放量"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "山西证券---华兰生物一季报点评：业绩符合市场预期，流感疫苗有望持续放量【公司研究】",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "2021年中国血液制品竞争格局及市场份额分析 细分产品企业表现良好(附批签发数据)",
            "features": {
                "keywords": [
                    "血液制品",
                    "竞争格局",
                    "市场份额",
                    "细分产品",
                    "批签发数据"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2021年中国血液制品竞争格局及市场份额分析 细分产品企业表现良好(附批签发数据)",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "华兰生物：持续推进研发培育新增长点",
            "features": {
                "keywords": [
                    "华兰生物",
                    "研发",
                    "新增长点"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华兰生物：持续推进研发培育新增长点",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]